<DOC>
	<DOCNO>NCT01334879</DOCNO>
	<brief_summary>This study investigate use high dose anti-VEGF agent treatment radiation retinopathy patient recalcitrant disease .</brief_summary>
	<brief_title>High Dose Intravitreal Ranibizumab Recalcitrant Radiation Retinopathy</brief_title>
	<detailed_description>This study open-label , Phase I study intravitreally administer ranibizumab subject radiation retinopathy . This single center , non-randomized , active treatment study involve 10 consecutive patient . This study evaluate safety tolerability high dose ( 2.0 mg ) intravitreal ranibizumab effect regression radiation retinopathy mean change visual acuity .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Inclusion Criteria Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 21 year History clinical diagnosis radiation retinopathy Subjects least 3 month 10 year radiation therapy History prior treatment radiation retinopathy incomplete response ( eg . persistent edema , presence hemorrhage , presence exudate , etc ETDRS best correct visual acuity 20/400 good study eye Ability return study visit Exclusion Criteria Subjects meet follow criterion exclude study : Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial Subject significantly compromise visual acuity study eye due concomitant ocular condition . Subjects undergone intraocular surgery within last 60 day . Subjects intravitreal antiVEGF treatment within 30 day . Subjects intravitreal triamcinolone acetonide within 4 month . Subjects laser within 60 day . Inability obtain photographs document CNV ( include difficulty venous access ) . Subject known adverse reaction fluorescein dye . Subject history medical condition would preclude schedule visit completion study . Aphakia absence posterior capsule study eye . Previous violation posterior capsule study eye also exclude unless result yttrium aluminum garnet ( YAG ) posterior capsulotomy association posterior chamber lens implantation.. History glaucoma filter surgery study eye . Concurrent use two therapy glaucoma . Uncontrolled glaucoma study eye ( defined intraocular pressure &gt; 30 mm Hg despite treatment antiglaucoma medication ) Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>radiation</keyword>
	<keyword>retinopathy</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>eye</keyword>
</DOC>